SCHEMBL3479995

SCHEMBL3479995

CN1CCN(c2ccc(F)c(F)c2)c2ccc(-c3ccc(CO)nn3)cc2C1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 10/20 0.44
SCD O00767 2/20 0.33
HDAC2 Q92769 1/20 0.32
RPS6KA3 P51812 2/20 0.32
RPS6KA2 Q15349 1/20 0.31
RPS6KA1 Q15418 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
FGFR1 P11362 1/20 0.31
FGFR3 P22607 1/20 0.31
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3228259 0.90 SCN9A (0.47) SCN9ASCDRPS6KA3
SCHEMBL3479601 0.88 SCN9A (0.43) SCN9ASCDSLC6A2SLC6A4SLC6A3
SCHEMBL3479691 0.88 SCN9A (0.45) SCN9ASLC6A2SLC6A4SLC6A3
SCHEMBL3479579 0.87 SCN9A (0.45) SCN9ASCDSLC6A2SLC6A4SLC6A3
SCHEMBL3223840 0.86 SCN9A (0.46) SCN9AFGFR1FGFR3SLC6A2SLC6A4
SCHEMBL3230412 0.86 SCN9A (0.42) SCN9ASLC6A2SLC6A4SLC6A3
SCHEMBL3230636 0.86 SCN9A (0.46) SCN9ASLC6A2SLC6A4SLC6A3
SCHEMBL3229179 0.86 SCN9A (0.46) SCN9AHDAC2RPS6KA3SLC6A2SLC6A4
SCHEMBL3229273 0.86 SCN9A (0.44) SCN9ASCDHDAC2RPS6KA3MEN1
SCHEMBL3479672 0.85 SCN9A (0.45) SCN9AFGFR1FGFR3SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885SCD 4386/4885HDAC2 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.